Steve N Caritis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3433970/publications.pdf

Version: 2024-02-01

330

all docs

328 27,915 83
papers citations h-index

330

docs citations

330 15810 times ranked citing authors

156

g-index

#	Article	IF	CITATIONS
1	Fetal Tachycardia in the Setting of Maternal Intrapartum Fever and Perinatal Morbidity. American Journal of Perinatology, 2024, 41, 160-166.	0.6	O
2	Racial and Ethnic Disparities in Adverse Perinatal Outcomes at Term. American Journal of Perinatology, 2023, 40, 557-566.	0.6	5
3	Antenatal Corticosteroids and Preterm Neonatal Morbidity and Mortality among Women with and without Diabetes in Pregnancy. American Journal of Perinatology, 2022, 39, 067-074.	0.6	8
4	Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy. British Journal of Clinical Pharmacology, 2022, 88, 271-281.	1.1	10
5	Association between Hypertensive Disorders of Pregnancy and Long-Term Neurodevelopmental Outcomes in the Offspring. American Journal of Perinatology, 2022, 39, 0921-0929.	0.6	4
6	An evaluation of seasonal maternal/neonatal morbidity related to trainee cycles. American Journal of Obstetrics & Synecology MFM, 2022, , 100583.	1.3	0
7	PREDICITION OF CEREBRAL PALSY OR DEATH AMONG PRETERM INFANTS WHO SURVIVE THE NEONATAL PERIOD. American Journal of Perinatology, 2022, , .	0.6	2
8	Predictive performance of newborn small for gestational age by a United States intrauterine vs birthweight-derived standard for short-term neonatal morbidity and mortality. American Journal of Obstetrics & Synecology MFM, 2022, 4, 100599.	1.3	0
9	Treatment of Gestational Diabetes Mellitus and Offspring Early Childhood Growth. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1849-e1858.	1.8	2
10	Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet, The, 2021, 397, 1183-1194.	6.3	110
11	Differences in obstetrical care and outcomes associated with the proportion of the obstetrician's shift completed. American Journal of Obstetrics and Gynecology, 2021, 225, 430.e1-430.e11.	0.7	0
12	A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. American Journal of Obstetrics and Gynecology, 2021, 225, 666.e1-666.e15.	0.7	47
13	Obstetrical, fetal, and lactation pharmacology—a crisis that can no longer be ignored. American Journal of Obstetrics and Gynecology, 2021, 225, 10-20.	0.7	20
14	Cervical length distribution and other sonographic ancillary findings of singleton nulliparous patients at midgestation. American Journal of Obstetrics and Gynecology, 2021, 225, 181.e1-181.e11.	0.7	3
15	Intrapartum Fetal Electrocardiogram in Small- and Large-for-Gestational Age Fetuses. American Journal of Perinatology, 2021, 38, 1465-1471.	0.6	0
16	Outcomes in Twins Compared With Singletons Subsequent to Preterm Prelabor Rupture of Membranes. Obstetrics and Gynecology, 2021, 138, 725-731.	1.2	1
17	Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. Frontiers in Pediatrics, 2021, 9, 733823.	0.9	17
18	A Possible Mechanism of Action of $17\hat{l}$ ±-Hydroxyprogesterone Caproate: Enhanced IL-10 Production. American Journal of Perinatology, 2021, , .	0.6	0

#	Article	IF	CITATIONS
19	Sex-Specific Genetic Susceptibility to Adverse Neurodevelopmental Outcome in Offspring of Pregnancies at Risk of Early Preterm Delivery. American Journal of Perinatology, 2020, 37, 281-290.	0.6	3
20	Duration of Operative Vaginal Delivery and Adverse Obstetric Outcomes. American Journal of Perinatology, 2020, 37, 503-510.	0.6	8
21	Pharmacokinetics and Pharmacodynamics. , 2020, , 581-587.e1.		0
22	Naltrexone use in pregnancy: a time for change. American Journal of Obstetrics and Gynecology, 2020, 222, 1-2.	0.7	18
23	Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. Clinical Pharmacology and Therapeutics, 2020, 107, 1362-1372.	2.3	8
24	Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. International Journal of Epidemiology, 2020, 49, 648-656.	0.9	21
25	Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2020, 60, 540-549.	1.0	4
26	Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations. Journal of Clinical Pharmacology, 2020, 60, 477-488.	1.0	8
27	Modelâ€Informed Dose Optimization in Pregnancy. Journal of Clinical Pharmacology, 2020, 60, S63-S76.	1.0	10
28	Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. Therapeutic Drug Monitoring, 2020, 42, 264-270.	1.0	26
29	Neonatal and Maternal Composite Adverse Outcomes Among Low-Risk Nulliparous Women Compared With Multiparous Women at 39–41 Weeks of Gestation. Obstetrics and Gynecology, 2020, 136, 450-457.	1.2	13
30	Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metabolism and Disposition, 2020, 48, 264-271.	1.7	31
31	Association Between Time of Day and the Decision for an Intrapartum Cesarean Delivery. Obstetrics and Gynecology, 2020, 135, 535-541.	1.2	3
32	Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation. American Journal of Perinatology, 2020, , .	0.6	1
33	A Model to Predict Vaginal Delivery and Maternal and Neonatal Morbidity in Low-Risk Nulliparous Patients at Term. American Journal of Perinatology, 2020, , .	0.6	0
34	Opioids affect the fetal brain: reframing the detoxification debate. American Journal of Obstetrics and Gynecology, 2019, 221, 602-608.	0.7	32
35	Cost-effectiveness of Antenatal Corticosteroid Therapy vs No Therapy in Women at Risk of Late Preterm Delivery. JAMA Pediatrics, 2019, 173, 462.	3. 3	25
36	Cord Blood Haptoglobin, Cerebral Palsy and Death in Infants of Women at Risk for Preterm Birth: A Secondary Analysis of a Randomised Controlled Trial. EClinicalMedicine, 2019, 9, 11-18.	3.2	4

#	Article	IF	CITATIONS
37	Reply. American Journal of Obstetrics and Gynecology, 2019, 220, 608-609.	0.7	O
38	Association of Labor With Neonatal Respiratory Outcomes at 36–40 Weeks of Gestation. Obstetrics and Gynecology, 2019, 134, 495-501.	1.2	3
39	In Reply. Obstetrics and Gynecology, 2019, 133, 190-191.	1.2	0
40	Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 83-89.	0.6	5
41	Response to Medical Nutritional Therapy and Need for Pharmacological Therapy in Women with Gestational Diabetes. American Journal of Perinatology, 2019, 36, 1250-1255.	0.6	2
42	Daytime Compared With Nighttime Differences in Management and Outcomes of Postpartum Hemorrhage. Obstetrics and Gynecology, 2019, 133, 155-162.	1.2	5
43	The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome. Paediatric and Perinatal Epidemiology, 2018, 32, 213-222.	0.8	23
44	Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate. American Journal of Perinatology, 2018, 35, 809-814.	0.6	4
45	Pregnancy outcomes in women with an early diagnosis of gestational diabetes mellitus. Diabetes Research and Clinical Practice, 2018, 138, 177-186.	1.1	33
46	Defining failed induction of labor. American Journal of Obstetrics and Gynecology, 2018, 218, 122.e1-122.e8.	0.7	75
47	Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth. American Journal of Perinatology, 2018, 35, 1012-1022.	0.6	11
48	Evaluation of 17-alpha hydroxyprogesterone caproateÂefficacy. American Journal of Obstetrics and Gynecology, 2018, 218, 261.	0.7	2
49	The Association of Decision-to-Incision Time for Cesarean Delivery with Maternal and Neonatal Outcomes. American Journal of Perinatology, 2018, 35, 247-253.	0.6	13
50	Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases. American Journal of Perinatology, 2018, 35, 470-480.	0.6	3
51	Association Between Gestational Weight Gain and Perinatal Outcomes. Obstetrics and Gynecology, 2018, 132, 875-881.	1.2	80
52	Maternal Outcomes Associated With Lower Range Stage 1 Hypertension. Obstetrics and Gynecology, 2018, 132, 843-849.	1.2	84
53	Defining the clinical response to 17-alpha hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2018, 219, 623-625.	0.7	3
54	Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. Hypertension, 2018, 72, 202-207.	1.3	50

#	Article	IF	CITATIONS
55	Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity. American Journal of Obstetrics and Gynecology, 2018, 219, 296.e1-296.e8.	0.7	21
56	Variation in the Nulliparous, Term, Singleton, Vertex Cesarean Delivery Rate. Obstetrics and Gynecology, 2018, 131, 1039-1048.	1.2	19
57	Prednisone Pharmacokinetics During Pregnancy and Lactation. Journal of Clinical Pharmacology, 2018, 58, 1223-1232.	1.0	29
58	Gestational changes in buprenorphine exposure: A physiologicallyâ€based pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2018, 84, 2075-2087.	1.1	26
59	Nausea and vomiting of pregnancy - What's new?. Autonomic Neuroscience: Basic and Clinical, 2017, 202, 62-72.	1.4	86
60	Neonatal outcomes following preterm birth classified according to placental features. American Journal of Obstetrics and Gynecology, 2017, 216, 411.e1-411.e14.	0.7	87
61	Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. New England Journal of Medicine, 2017, 376, 815-825.	13.9	363
62	The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2017, 217, 369.e1-369.e9.	0.7	9
63	Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. JAMA - Journal of the American Medical Association, 2017, 317, 1047.	3.8	142
64	Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a retrospective cohort study. American Journal of Obstetrics and Gynecology, 2017, 216, 418.e1-418.e5.	0.7	26
65	Glycemic Control and Pregnancy Outcomes in Women with Type 2 Diabetes Treated with Oral Hypoglycemic Agents. American Journal of Perinatology, 2017, 34, 697-704.	0.6	3
66	Predictive Characteristics of Elevated 1-Hour Glucose Challenge Test Results for Gestational Diabetes. American Journal of Perinatology, 2017, 34, 1464-1469.	0.6	1
67	A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. British Journal of Clinical Pharmacology, 2017, 83, 2458-2473.	1.1	23
68	Role of early second-trimester uterine artery Doppler screening to predict small-for-gestational-age babies in nulliparous women. American Journal of Obstetrics and Gynecology, 2017, 217, 594.e1-594.e10.	0.7	45
69	Neonatal Morbidity of Small- and Large-for-Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. Obstetrics and Gynecology, 2017, 130, 511-519.	1.2	101
70	Racial and Ethnic Differences in Utilization of Labor Management Strategies Intended to Reduce Cesarean Delivery Rates. Obstetrics and Gynecology, 2017, 130, 1285-1294.	1.2	47
71	An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. American Journal of Obstetrics and Gynecology, 2017, 217, 459.e1-459.e6.	0.7	41
72	Placental maternal vascular malperfusion and adverse pregnancy outcomes in gestational diabetes mellitus. Placenta, 2017, 49, 10-15.	0.7	60

#	Article	IF	Citations
73	Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. American Journal of Obstetrics and Gynecology, 2017, 216, 64.e1-64.e7.	0.7	46
74	Association of Cervical Effacement With the Rate of Cervical Change in Labor Among Nulliparous Women. Obstetrics and Gynecology, 2016, 127, 489-495.	1.2	6
75	Carpenter-Coustan Compared With National Diabetes Data Group Criteria for Diagnosing Gestational Diabetes. Obstetrics and Gynecology, 2016, 127, 893-898.	1.2	36
76	Population pharmacokinetics of 17αâ€hydroxyprogesterone caproate in singleton gestation. British Journal of Clinical Pharmacology, 2016, 82, 1084-1093.	1.1	12
77	Association of the Duration of Active Pushing With Obstetric Outcomes. Obstetrics and Gynecology, 2016, 127, 667-673.	1.2	73
78	Evaluation of delivery options for second-stage events. American Journal of Obstetrics and Gynecology, 2016, 214, 638.e1-638.e10.	0.7	60
79	What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth. Seminars in Perinatology, 2016, 40, 273-280.	1.1	7
80	Effectiveness of doxylamine-pyridoxine for morning sickness. American Journal of Obstetrics and Gynecology, 2016, 214, 664-666.	0.7	7
81	Racial/Ethnic Disparities in Measures of Self-reported Psychosocial States and Traits during Pregnancy. American Journal of Perinatology, 2016, 33, 1426-1432.	0.6	43
82	Ondansetron Exposure Changes in a Pregnant Woman. Pharmacotherapy, 2016, 36, e139-e141.	1.2	14
83	Polymorphisms in <i>CYP1A1</i> and <i>CYP3A5</i> Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting. Pharmacotherapy, 2016, 36, 1238-1244.	1.2	6
84	Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. BMC Pregnancy and Childbirth, 2016, 16, 371.	0.9	5
85	Maternal and Neonatal Outcomes With Early Compared With Delayed Pushing Among Nulliparous Women. Obstetrics and Gynecology, 2016, 128, 1039-1047.	1.2	20
86	Prediction of Spontaneous Preterm Birth Among Nulliparous Women With a Short Cervix. Journal of Ultrasound in Medicine, 2016, 35, 1293-1297.	0.8	21
87	Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of Clinical Pharmacology, 2016, 56, 581-589.	1.0	52
88	Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy. American Journal of Obstetrics and Gynecology, 2016, 215, 93.e1-93.e4.	0.7	4
89	Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. New England Journal of Medicine, 2016, 374, 1311-1320.	13.9	546
90	Timing of delivery and pregnancy outcomes in women withÂgestationalÂdiabetes. American Journal of Obstetrics and Gynecology, 2016, 215, 243.e1-243.e7.	0.7	18

#	Article	IF	Citations
91	Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. American Journal of Obstetrics and Gynecology, 2016, 214, 720.e1-720.e17.	0.7	202
92	Preterm neonatal morbidity and mortality by gestational age: aÂcontemporary cohort. American Journal of Obstetrics and Gynecology, 2016, 215, 103.e1-103.e14.	0.7	333
93	Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. Xenobiotica, 2016, 46, 169-174.	0.5	6
94	Racial and Ethnic Disparities in Maternal Morbidity and Obstetric Care. Obstetrics and Gynecology, 2015, 125, 1460-1467.	1.2	172
95	Population pharmacokinetics of oseltamivir in nonâ€pregnant and pregnant women. British Journal of Clinical Pharmacology, 2015, 80, 1042-1050.	1.1	22
96	Serious maternal complications after early preterm delivery (24-33 weeks' gestation). American Journal of Obstetrics and Gynecology, 2015, 213, 538.e1-538.e9.	0.7	80
97	Timing of treatment initiation for mild gestational diabetes mellitus and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2015, 213, 560.e1-560.e8.	0.7	22
98	Effect of Magnesium Sulfate Administration for Neuroprotection on Latency in Women with Preterm Premature Rupture of Membranes. American Journal of Perinatology, 2015, 32, 387-392.	0.6	12
99	A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b). American Journal of Obstetrics and Gynecology, 2015, 212, 539.e1-539.e24.	0.7	160
100	Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy and Childbirth, 2015, 15, 59.	0.9	31
101	The Association of Cord Serum Cytokines with Neurodevelopmental Outcomes. American Journal of Perinatology, 2015, 30, 115-122.	0.6	26
102	Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. American Journal of Obstetrics and Gynecology, 2015, 213, 541.e1-541.e7.	0.7	44
103	Relation between Birth Weight and Weight and Height at the Age of 2 in Children Born Preterm. American Journal of Perinatology, 2015, 32, 591-598.	0.6	1
104	Pharmacokinetics of drugs in pregnancy. Seminars in Perinatology, 2015, 39, 512-519.	1.1	233
105	Uterine endoplasmic reticulum stress-unfolded protein response regulation of gestational length is caspase-3 and -7–dependent. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14090-14095.	3.3	28
106	Glyburide vs Insulin and Adverse Pregnancy Outcomes. JAMA Pediatrics, 2015, 169, 974.	3.3	0
107	A Randomized Trial of Intrapartum Fetal ECG ST-Segment Analysis. New England Journal of Medicine, 2015, 373, 632-641.	13.9	135
108	Antenatal Magnesium and Cerebral Palsy in Preterm Infants. Journal of Pediatrics, 2015, 167, 834-839.e3.	0.9	37

#	Article	IF	CITATIONS
109	Nonmedically indicated induction vs expectant treatment in term nulliparous women. American Journal of Obstetrics and Gynecology, 2015, 212, 103.e1-103.e7.	0.7	39
110	Umbilical Cord Serum Interleukin-6, C-Reactive Protein, and Myeloperoxidase Concentrations at Birth and Association with Neonatal Morbidities and Long-Term Neurodevelopmental Outcomes. American Journal of Perinatology, 2014, 31, 717-726.	0.6	30
111	Accuracy of Sonographic Chorionicity Classification in Twin Gestations. Journal of Ultrasound in Medicine, 2014, 33, 2187-2192.	0.8	37
112	Maternal Vitamin D Status and Small-for-Gestational-Age Offspring in Women at High Risk for Preeclampsia. Obstetrics and Gynecology, 2014, 123, 40-48.	1.2	73
113	Frequency of and Factors Associated With Severe Maternal Morbidity. Obstetrics and Gynecology, 2014, 123, 804-810.	1.2	176
114	Stability of hydroxyprogesterone caproate alone and in a compounded pharmaceutical product. American Journal of Health-System Pharmacy, 2014, 71, 1120-1127.	0.5	2
115	Quality assessment of compounded 17-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2014, 210, 47.e1-47.e7.	0.7	12
116	Pharmacokinetics of Indomethacin in Pregnancy. Clinical Pharmacokinetics, 2014, 53, 545-551.	1.6	20
117	Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2014, 210, 128.e1-128.e6.	0.7	45
118	Oseltamivir for influenza in pregnancy. Seminars in Perinatology, 2014, 38, 503-507.	1.1	13
119	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: Pharmacologic considerations. Seminars in Perinatology, 2014, 38, 516-522.	1.1	19
120	Studying the antiemetic effect of vitamin B6 for morning sickness: Pyridoxine and pyridoxal are prodrugs. Journal of Clinical Pharmacology, 2014, 54, 1429-1433.	1.0	8
121	Can differences in obstetric outcomes be explained by differences in the care provided? The MFMU Network APEX study. American Journal of Obstetrics and Gynecology, 2014, 211, 147.e1-147.e16.	0.7	75
122	Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes. American Journal of Obstetrics and Gynecology, 2014, 211, 412.e1-412.e6.	0.7	3
123	Adherence to criteria for transvaginal ultrasound imaging andÂmeasurement of cervical length. American Journal of Obstetrics and Gynecology, 2013, 209, 365.e1-365.e5.	0.7	36
124	Uterine Contraction Agents and Tocolytics. , 2013, , 307-330.		3
125	A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2013, 74, 126-132.	1.4	42
126	The association of cerebral palsy and death with small-for-gestational-age birthweight in preterm neonates by individualized and population-based percentiles. American Journal of Obstetrics and Gynecology, 2013, 209, 340.e1-340.e5.	0.7	20

#	Article	IF	CITATIONS
127	Comparing the Pharmacokinetics of Doxylamine/Pyridoxine Delayedâ€Release Combination in Nonpregnant Women of Reproductive Age and Women in the First Trimester of Pregnancy. Journal of Clinical Pharmacology, 2013, 53, 334-338.	1.0	7
128	Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2013, 208, 470.e1-470.e5.	0.7	7
129	Advanced lipoprotein measures and recurrent preterm birth. American Journal of Obstetrics and Gynecology, 2013, 209, 342.e1-342.e7.	0.7	8
130	Reply. American Journal of Obstetrics and Gynecology, 2013, 209, 285-286.	0.7	0
131	Reply. American Journal of Obstetrics and Gynecology, 2013, 208, 337-338.	0.7	0
132	Gestational age–specific risks vs benefits of multicourse antenatal corticosteroids for preterm labor. American Journal of Obstetrics and Gynecology, 2013, 209, 330.e1-330.e7.	0.7	20
133	Effect of endogenous steroid hormones on 17-alpha-hydroxyprogesterone caproate metabolism. American Journal of Obstetrics and Gynecology, 2013, 208, 86.e1-86.e6.	0.7	11
134	Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals. American Journal of Obstetrics and Gynecology, 2013, 209, 446.e1-446.e30.	0.7	77
135	Relationship Between 1-Hour Glucose Challenge Test Results and Perinatal Outcomes. Obstetrics and Gynecology, 2013, 121, 1241-1247.	1.2	21
136	Population versus Customized Fetal Growth Norms and Adverse Outcomes in an Intrapartum Cohort. American Journal of Perinatology, 2013, 30, 335-342.	0.6	16
137	Customized versus Population Approach for Evaluation of Fetal Overgrowth. American Journal of Perinatology, 2013, 30, 565-572.	0.6	14
138	Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic. American Journal of Perinatology, 2013, 30, 275-282.	0.6	38
139	The Impact of Tobacco Use on Preterm Premature Rupture of the Membranes. American Journal of Perinatology, 2013, 30, 185-190.	0.6	1
140	The Obstetric and Neonatal Implications of a Low Value on the 50-g Glucose Screening Test. American Journal of Perinatology, 2013, 30, 715-722.	0.6	7
141	Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes. Drug Metabolism and Disposition, 2013, 41, 296-304.	1.7	32
142	Change in Mononuclear Leukocyte Responsiveness in Midpregnancy and Subsequent Preterm Birth. Obstetrics and Gynecology, 2013, 121, 805-811.	1.2	21
143	A Pharmacologic Approach to the Use of Glyburide in Pregnancy. Obstetrics and Gynecology, 2013, 121, 1309-1312.	1.2	32
144	Timing of Delivery and Adverse Outcomes in Term Singleton Repeat Cesarean Deliveries. Obstetrics and Gynecology, 2013, 121, 561-569.	1.2	69

#	Article	IF	CITATIONS
145	Activity Restriction Among Women With a Short Cervix. Obstetrics and Gynecology, 2013, 121, 1181-1186.	1.2	56
146	Relationship between Fetal Station and Successful Vaginal Delivery in Nulliparous Women. American Journal of Perinatology, 2012, 29, 723-730.	0.6	8
147	Impact of Smoking during Pregnancy on Functional Coagulation Testing. American Journal of Perinatology, 2012, 29, 225-230.	0.6	2
148	Determinants of Adherence to Delayed-Release Doxylamine and Pyridoxine in Patients With Nausea and Vomiting of Pregnancy. Therapeutic Drug Monitoring, 2012, 34, 569-573.	1.0	5
149	Risk of Uterine Rupture and Placenta Accreta With Prior Uterine Surgery Outside of the Lower Segment. Obstetrics and Gynecology, 2012, 120, 1332-1337.	1.2	92
150	Association of Polymorphisms in Neuroprotection and Oxidative Stress Genes and Neurodevelopmental Outcomes After Preterm Birth. Obstetrics and Gynecology, 2012, 120, 542-550.	1.2	19
151	Cervical pessary use and preterm birth: how little we know. Lancet, The, 2012, 379, 1769-1770.	6.3	7
152	Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology, 2012, 207, 396.e1-396.e8.	0.7	36
153	Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American Journal of Obstetrics and Gynecology, 2012, 207, 398.e1-398.e8.	0.7	48
154	17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology, 2012, 207, 390.e1-390.e8.	0.7	127
155	14: Effect of prescription medications on 17-alpha-hydroxyprogesterone caproate (17-OHPC) metabolism. American Journal of Obstetrics and Gynecology, 2012, 206, S9.	0.7	3
156	Timing of delivery and pregnancy outcomes among laboring nulliparous women. American Journal of Obstetrics and Gynecology, 2012, 206, 239.e1-239.e8.	0.7	14
157	Elective repeat cesarean delivery compared with spontaneous trial of labor after a prior cesarean delivery: a propensity score analysis. American Journal of Obstetrics and Gynecology, 2012, 206, 311.e1-311.e9.	0.7	38
158	Fetal male gender and the benefits of treatment of mild gestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 2012, 206, 422.e1-422.e5.	0.7	22
159	Association of Cord Blood Magnesium Concentration and Neonatal Resuscitation. Journal of Pediatrics, 2012, 160, 573-577.e1.	0.9	29
160	Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials. BMC Pregnancy and Childbirth, 2012, 12, 13.	0.9	14
161	Perinatal Outcomes in Hispanic and Non-Hispanic White Women With Mild Gestational Diabetes. Obstetrics and Gynecology, 2012, 120, 1099-1104.	1,2	13
162	Failed Labor Induction Toward an Objective Diagnosis. Obstetrical and Gynecological Survey, 2011, 66, 265-266.	0.2	1

#	Article	IF	Citations
163	Timing of Elective Repeat Cesarean Delivery at Term and Maternal Perioperative Outcomes. Obstetrics and Gynecology, 2011, 117, 280-286.	1.2	74
164	Failed Labor Induction. Obstetrics and Gynecology, 2011, 117, 267-272.	1.2	79
165	Admixture Mapping to Identify Spontaneous Preterm Birth Susceptibility Loci in African Americans. Obstetrics and Gynecology, 2011, 117, 1078-1084.	1.2	20
166	The Effect of Plurality and Obesity on Betamethasone Concentrations in Women at Risk for Preterm Delivery. Obstetrical and Gynecological Survey, 2011, 66, 1-2.	0.2	2
167	The Relationship Between Maternal Glycemia and Perinatal Outcome. Obstetrics and Gynecology, 2011, 117, 218-224.	1.2	132
168	Effect of Antibiotic Exposure on Nugent Score Among Pregnant Women With and Without Bacterial Vaginosis. Obstetrics and Gynecology, 2011, 117, 844-849.	1.2	10
169	The change in the rate of vaginal birth after caesarean section. Paediatric and Perinatal Epidemiology, 2011, 25, 37-43.	0.8	43
170	50: Effects of endogenous steroids on 17alpha-hydroxyprogesterone caproate (17-OHPC) metabolism. American Journal of Obstetrics and Gynecology, 2011, 204, S29.	0.7	2
171	Metaanalysis and labor inhibition therapy. American Journal of Obstetrics and Gynecology, 2011, 204, 95-96.	0.7	5
172	Placental endothelial nitric oxide synthase in multiple and single dose betamethasone exposed pregnancies. American Journal of Obstetrics and Gynecology, 2011, 204, 545.e11-545.e16.	0.7	3
173	Repeated course antenatal steroids, inflammation gene polymorphisms, and neurodevelopmental outcomes at age 2. American Journal of Obstetrics and Gynecology, 2011, 205, 79.e1-79.e5.	0.7	2
174	Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. American Journal of Obstetrics and Gynecology, 2011, 204, S84-S88.	0.7	68
175	Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. American Journal of Obstetrics and Gynecology, 2011, 205, 40.e1-40.e8.	0.7	40
176	Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2011, 205, 135.e1-135.e9.	0.7	56
177	Fish Consumption, Erythrocyte Fatty Acids, and Preterm Birth. Obstetrics and Gynecology, 2011, 117, 1071-1077.	1.2	44
178	Omega-3 Fatty Acid Supplementation to Prevent Recurrent Preterm Birth. Obstetrics and Gynecology, 2010, 115, 234-242.	1.2	96
179	Prothrombin Gene G20210A Mutation and Obstetric Complications. Obstetrics and Gynecology, 2010, 115, 14-20.	1.2	144
180	Comparison of Transverse and Vertical Skin Incision for Emergency Cesarean Delivery. Obstetrics and Gynecology, 2010, 115, 1134-1140.	1.2	102

#	Article	IF	Citations
181	The Effect of Active and Passive Household Cigarette Smoke Exposure on Pregnant Women With Asthma. Chest, 2010, 137, 601-608.	0.4	38
182	Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for Factor V Leiden. Journal of Reproductive Immunology, 2010, 85, 180-185.	0.8	4
183	The effect of maternal body mass index on neonatal outcome in women receiving a single course of antenatal corticosteroids. American Journal of Obstetrics and Gynecology, 2010, 202, 263.e1-263.e5.	0.7	20
184	Association of fetal inflammation and coagulation pathway gene polymorphisms with neurodevelopmental delay at age 2 years. American Journal of Obstetrics and Gynecology, 2010, 203, 83.e1-83.e10.	0.7	24
185	The effect of plurality and obesity on betamethasone concentrations in women at risk for preterm delivery. American Journal of Obstetrics and Gynecology, 2010, 203, 219.e1-219.e5.	0.7	47
186	Beta adrenergic agonists and neonatal outcome. American Journal of Obstetrics and Gynecology, 2010, 203, e16-e17.	0.7	1
187	Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. American Journal of Obstetrics and Gynecology, 2010, 203, 571.e1-571.e7.	0.7	126
188	Avascular Villi, Increased Syncytial Knots, and Hypervascular Villi Are Associated with Pregnancies Complicated by Factor V Leiden Mutation. Pediatric and Developmental Pathology, 2010, 13, 341-347.	0.5	35
189	Metabolism of 17α-Hydroxyprogesterone Caproate, an Agent for Preventing Preterm Birth, by Fetal Hepatocytes. Drug Metabolism and Disposition, 2010, 38, 723-727.	1.7	21
190	Neonatal Outcomes and Operative Vaginal Delivery Versus Cesarean Delivery. American Journal of Perinatology, 2010, 27, 493-499.	0.6	27
191	The Relationship of Asthma-Specific Quality of Life During Pregnancy to Subsequent Asthma and Perinatal Morbidity. Journal of Asthma, 2010, 47, 46-50.	0.9	28
192	Neonatal Outcomes in Twin Pregnancies Delivered Moderately Preterm, Late Preterm, and Term. American Journal of Perinatology, 2010, 27, 537-542.	0.6	70
193	Maternal Serum Interleukin-6, C-Reactive Protein, and Matrix Metalloproteinase-9 Concentrations as Risk Factors for Preterm Birth <32 Weeks and Adverse Neonatal Outcomes. American Journal of Perinatology, 2010, 27, 631-640.	0.6	139
194	Maternal and Neonatal Outcomes of Repeat Cesarean Delivery in Women with a Prior Classical versus Low Transverse Uterine Incision. American Journal of Perinatology, 2010, 27, 791-796.	0.6	27
195	Mode of Delivery in Women with Antepartum Fetal Death and Prior Cesarean Delivery. American Journal of Perinatology, 2010, 27, 825-830.	0.6	26
196	Second trimester cervical length and risk of preterm birth in women with twin gestations treated with $17-\hat{l}\pm$ hydroxyprogesterone caproate. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1360-1364.	0.7	57
197	The Frequency and Complication Rates of Hysterectomy Accompanying Cesarean Delivery. Obstetrics and Gynecology, 2009, 114, 224-229.	1.2	239
198	Perioperative Antibiotic Prophylaxis for Nonlaboring Cesarean Delivery. Obstetrics and Gynecology, 2009, 114, 752-756.	1.2	35

#	Article	IF	Citations
199	Maternal Obesity, Uterine Activity, and the Risk of Spontaneous Preterm Birth. Obstetrics and Gynecology, 2009, 113, 48-52.	1.2	53
200	Bone Metabolism in Fetuses of Pregnant Women Exposed to Single and Multiple Courses of Corticosteroids. Obstetrics and Gynecology, 2009, 114, 38-44.	1.2	12
201	Prevention of Preterm Birth in Triplets Using 17 Alpha-Hydroxyprogesterone Caproate. Obstetrics and Gynecology, 2009, 113, 285-292.	1.2	116
202	Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2009, 200, 630.e1-630.e8.	0.7	28
203	The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology, 2009, 201, 392.e1-392.e5.	0.7	39
204	Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2009, 201, 357.e1-357.e7.	0.7	211
205	Can a prediction model for vaginal birth after cesarean also predict the probability of morbidity related to a trial of labor?. American Journal of Obstetrics and Gynecology, 2009, 200, 56.e1-56.e6.	0.7	99
206	Timing of Elective Repeat Cesarean Delivery at Term and Neonatal Outcomes. New England Journal of Medicine, 2009, 360, 111-120.	13.9	749
207	A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy. Obstetrical and Gynecological Survey, 2009, 64, 15-17.	0.2	14
208	Failed Operative Vaginal Delivery. Obstetrics and Gynecology, 2009, 114, 1017-1022.	1.2	46
209	Simultaneous quantitation of 17α-hydroxyprogesterone caproate, 17α-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography–mass spectrometry (HPLC–MS/MS). Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 1174-1180.	1.4	33
210	Human decidual cell Toll-like receptor signaling in response to endotoxin: The effect of progestins. American Journal of Obstetrics and Gynecology, 2008, 198, 119.e1-119.e4.	0.7	13
211	Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology, 2008, 199, 506.e1-506.e7.	0.7	25
212	Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. American Journal of Obstetrics and Gynecology, 2008, 199, 30.e1-30.e5.	0.7	74
213	Maternal and fetal Toll-like receptor 4 genotype and chorionic plate inflammatory lesions. American Journal of Obstetrics and Gynecology, 2008, 199, 400.e1-400.e4.	0.7	22
214	A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy. New England Journal of Medicine, 2008, 359, 895-905.	13.9	664
215	Identification of Enzymes Involved in the Metabolism of 17α-Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth. Drug Metabolism and Disposition, 2008, 36, 1896-1902.	1.7	29
216	Cesarean Delivery for the Second Twin. Obstetrics and Gynecology, 2008, 112, 748-752.	1.2	36

#	Article	IF	Citations
217	Previous Preterm Cesarean Delivery and Risk of Subsequent Uterine Rupture. Obstetrics and Gynecology, 2008, 111, 648-653.	1.2	100
218	Bone Metabolism in Pregnant Women Exposed to Single Compared With Multiple Courses of Corticosteroids. Obstetrics and Gynecology, 2008, 111, 1352-1358.	1.2	5
219	Pregnancy Outcomes for Women With Placenta Previa in Relation to the Number of Prior Cesarean Deliveries. Obstetrics and Gynecology, 2007, 110, 1249-1255.	1.2	133
220	Perioperative Morbidity and Mortality Among Human Immunodeficiency Virus–Infected Women Undergoing Cesarean Delivery. Obstetrics and Gynecology, 2007, 110, 385-390.	1.2	45
221	Outcomes of Induction of Labor After One Prior Cesarean. Obstetrics and Gynecology, 2007, 109, 262-269.	1.2	110
222	Fetal Pulse Oximetry and Cesarean Delivery. Obstetrical and Gynecological Survey, 2007, 62, 227-228.	0.2	1
223	Comparison of Maternal and Infant Outcomes From Primary Cesarean Delivery During the Second Compared With First Stage of Labor. Obstetrics and Gynecology, 2007, 109, 917-921.	1.2	179
224	Development of a Nomogram for Prediction of Vaginal Birth After Cesarean Delivery. Obstetrics and Gynecology, 2007, 109, 806-812.	1.2	409
225	Prevention of Preterm Delivery. New England Journal of Medicine, 2007, 357, 477-487.	13.9	413
226	Long-Term Outcomes after Repeat Doses of Antenatal Corticosteroids. New England Journal of Medicine, 2007, 357, 1190-1198.	13.9	287
227	A Trial of 17 Alpha-Hydroxyprogesterone Caproate to Prevent Prematurity in Twins. New England Journal of Medicine, 2007, 357, 454-461.	13.9	354
228	Development and validation of a high-performance liquid chromatography–mass spectrometric assay for the determination of 17α-hydroxyprogesterone caproate (17-OHPC) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 856, 141-147.	1.2	7
229	Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. American Journal of Obstetrics and Gynecology, 2007, 197, 599.e1-599.e7.	0.7	69
230	The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects of Antenatal Repeated Steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. American Journal of Obstetrics and Gynecology, 2007, 197, 281.e1-281.e8.	0.7	31
231			
	Fetal Injury Associated With Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 885-890.	1.2	214
232	Fetal Injury Associated With Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 885-890. Blood Transfusion and Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 891-897.	1.2	118
232			

#	Article	IF	Citations
235	Decision-to-Incision Times and Maternal and Infant Outcomes. Obstetrics and Gynecology, 2006, 108, 6-11.	1.2	192
236	Association of Obesity With Pulmonary and Nonpulmonary Complications of Pregnancy in Asthmatic Women. Obstetrics and Gynecology, 2006, 108, 77-82.	1.2	70
237	Spirometry is related to perinatal outcomes in pregnant women with asthma. American Journal of Obstetrics and Gynecology, 2006, 194, 120-126.	0.7	115
238	Midpregnancy genitourinary tract infection with Chlamydia trachomatis: Association with subsequent preterm delivery in women with bacterial vaginosis and Trichomonas vaginalis. American Journal of Obstetrics and Gynecology, 2006, 194, 493-500.	0.7	61
239	Are women with recurrent spontaneous preterm births different from those without such history?. American Journal of Obstetrics and Gynecology, 2006, 194, 1176-1184.	0.7	53
240	A prospective masked observational study of uterine contraction frequency in twins. American Journal of Obstetrics and Gynecology, 2006, 195, 1564-1570.	0.7	28
241	Single versus weekly courses of antenatal corticosteroids: Evaluation of safety and efficacy. American Journal of Obstetrics and Gynecology, 2006, 195, 633-642.	0.7	271
242	The MFMU Cesarean Registry: Impact of fetal size on trialÂof labor success for patients with previous cesareanÂfor dystocia. American Journal of Obstetrics and Gynecology, 2006, 195, 1127-1131.	0.7	51
243	The MFMU Cesarean Registry: Impact of time of day on cesarean complications. American Journal of Obstetrics and Gynecology, 2006, 195, 1132-1137.	0.7	45
244	The Maternal-Fetal Medicine Units Cesarean Registry: Safety and efficacy of a trial of labor in preterm pregnancy after aÂprior cesarean delivery. American Journal of Obstetrics and Gynecology, 2006, 195, 1119-1126.	0.7	90
245	Trial of Labor or Repeat Cesarean Delivery in Women With Morbid Obesity and Previous Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 125-133.	1.2	167
246	Antioxidants and the Prevention of Preeclampsia $\hat{a} \in$ "Unresolved Issues. New England Journal of Medicine, 2006, 354, 1841-1843.	13.9	34
247	Fetal Pulse Oximetry and Cesarean Delivery. New England Journal of Medicine, 2006, 355, 2195-2202.	13.9	143
248	Complications of Anesthesia for Cesarean Delivery. Obstetrics and Gynecology, 2005, 106, 281-287.	1.2	85
249	Spontaneous Resolution of Asymptomatic Chlamydia trachomatis in Pregnancy. Obstetrics and Gynecology, 2005, 105, 557-562.	1.2	30
250	The vaginal inflammatory milieu and the risk of early premature preterm rupture of membranes. American Journal of Obstetrics and Gynecology, 2005, 192, 213-218.	0.7	48
251	Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. American Journal of Obstetrics and Gynecology, 2005, 192, 633-639.	0.7	346
252	The Preterm Prediction study: Association between maternal body mass index and spontaneous and indicated preterm birth. American Journal of Obstetrics and Gynecology, 2005, 192, 882-886.	0.7	273

#	Article	IF	Citations
253	The Maternal-Fetal Medicine Unit cesarean registry: Trial of labor with a twin gestation. American Journal of Obstetrics and Gynecology, 2005, 193, 135-140.	0.7	57
254	Differences in inflammatory cytokine and Toll-like receptor genes and bacterial vaginosis in pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, 1478-1485.	0.7	45
255	Cervical anti-inflammatory cytokine concentrations among first-trimester pregnant smokers. American Journal of Obstetrics and Gynecology, 2005, 193, 1999-2003.	0.7	32
256	The MFMU Cesarean Registry: Factors affecting the success of trial of labor after previous cesarean delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1016-1023.	0.7	410
257	Progesterone for prevention of recurrent preterm birth: Impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1127-1131.	0.7	88
258	Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1181-1186.	0.7	34
259	The MFMU Cesarean Registry: Uterine atony after primary cesarean delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1056-1060.	0.7	60
260	Adverse effects of tocolytic therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 74-78.	1.1	29
261	Does Progesterone Treatment Influence Risk Factors for Recurrent Preterm Delivery?. Obstetrics and Gynecology, 2005, 106, 557-561.	1.2	33
262	Is there a seasonal variation in the diagnosis of oligohydramnios?. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 17, 173-177.	0.7	2
263	Asthma During Pregnancy. Obstetrics and Gynecology, 2004, 103, 5-12.	1.2	173
264	Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. American Journal of Obstetrics and Gynecology, 2004, 190, 737-744.	0.7	102
265	Is early-pregnancy proteinuria associated with an increased rate of preeclampsia in women with pregestational diabetes mellitus?. American Journal of Obstetrics and Gynecology, 2004, 190, 775-778.	0.7	21
266	The maternal-fetal medicine units cesarean registry: chorioamnionitis at term and its durationâ€"relationship to outcomes. American Journal of Obstetrics and Gynecology, 2004, 191, 211-216.	0.7	232
267	Frequency of uterine contractions in asymptomatic pregnant women with or without a short cervix on transvaginal ultrasound scan. American Journal of Obstetrics and Gynecology, 2004, 191, 1253-1256.	0.7	42
268	The relationship of asthma medication use to perinatal outcomes. Journal of Allergy and Clinical Immunology, 2004, 113, 1040-1045.	1.5	189
269	Maternal and Perinatal Outcomes Associated with a Trial of Labor after Prior Cesarean Delivery. New England Journal of Medicine, 2004, 351, 2581-2589.	13.9	1,166
270	An Evidence-Based Approach to the Evaluation and Treatment of Premature Rupture of Membranes: Part I. Obstetrical and Gynecological Survey, 2004, 59, 669-677.	0.2	40

#	Article	IF	Citations
271	An Evidence-Based Approach to the Evaluation and Treatment of Premature Rupture of Membranes: Part II. Obstetrical and Gynecological Survey, 2004, 59, 678-689.	0.2	14
272	Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. American Journal of Obstetrics and Gynecology, 2003, 189, 560-567.	0.7	79
273	Elevated vaginal pH and neutrophils are associated strongly with early spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2003, 189, 1150-1154.	0.7	69
274	Interleukin-6 promoter â^'174 polymorphism and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2003, 189, 915-918.	0.7	102
275	What we have learned about preeclampsia. Seminars in Perinatology, 2003, 27, 239-246.	1.1	138
276	Randomized Clinical Trial of Metronidazole Plus Erythromycin to Prevent Spontaneous Preterm Delivery in Fetal Fibronectin–Positive Women. Obstetrics and Gynecology, 2003, 101, 847-855.	1.2	97
277	Tumor necrosis factor–α promoter gene polymorphism -308 and chorioamnionitis. Obstetrics and Gynecology, 2003, 102, 162-166.	1.2	28
278	Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate. New England Journal of Medicine, 2003, 348, 2379-2385.	13.9	1,472
279	Randomized Clinical Trial of Metronidazole Plus Erythromycin to Prevent Spontaneous Preterm Delivery in Fetal Fibronectin–Positive Women. Obstetrics and Gynecology, 2003, 101, 847-855.	1.2	101
280	Frequency of Uterine Contractions and the Risk of Spontaneous Preterm Delivery. New England Journal of Medicine, 2002, 346, 250-255.	13.9	185
281	Pharmacologic Inhibition of Preterm Labor. Clinical Obstetrics and Gynecology, 2002, 45, 99-113.	0.6	29
282	Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. American Journal of Obstetrics and Gynecology, 2002, 186, 66-71.	0.7	303
283	Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. American Journal of Obstetrics and Gynecology, 2002, 186, 422-426.	0.7	192
284	The Preterm Prediction Study: Elevated cervical ferritin levels at 22 to 24 weeks of gestation are associated with spontaneous preterm delivery in asymptomatic women. American Journal of Obstetrics and Gynecology, 2002, 186, 458-463.	0.7	35
285	The Preterm Prediction Study: The value of serum alkaline phosphatase, α-fetoprotein, plasma corticotropin-releasing hormone, and other serum markers for the prediction of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2002, 186, 990-996.	0.7	89
286	The Preterm Prediction Study: Association between cervical interleukin 6 concentration and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2001, 184, 483-488.	0.7	117
287	Antiphospholipid antibodies in women at risk for preeclampsia. American Journal of Obstetrics and Gynecology, 2001, 184, 825-834.	0.7	93
288	The Preterm Prediction Study: Toward a multiple-marker test for spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2001, 185, 643-651.	0.7	158

#	Article	IF	Citations
289	The Preterm Prediction Study: Granulocyte colony-stimulating factor and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 182, 625-630.	0.7	93
290	The Preterm Prediction Study: Cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. American Journal of Obstetrics and Gynecology, 2000, 182, 631-635.	0.7	47
291	The Preterm Prediction Study: Sequential cervical length and fetal fibronectin testing for the prediction of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 182, 636-643.	0.7	123
292	The Preterm Prediction Study: Association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 183, 662-668.	0.7	173
293	The Preterm Prediction Study: Prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. American Journal of Obstetrics and Gynecology, 2000, 183, 738-745.	0.7	315
294	The Preterm Prediction Study: Quantitative fetal fibronectin values and the prediction of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 183, 1480-1483.	0.7	73
295	Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. American Journal of Obstetrics and Gynecology, 2000, 183, 1520-1524.	0.7	170
296	Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 2000, 182, 364-369.	0.7	187
297	Hypertensive disorders in twin versus singleton gestations. American Journal of Obstetrics and Gynecology, 2000, 182, 938-942.	0.7	454
298	PRETERM PREDICTION STUDY: IS SOCIOECONOMIC STATUS A RISK FACTOR FOR BACTERIAL VAGINOSIS IN BLACK OR IN WHITE WOMEN?. American Journal of Perinatology, 2000, Volume 17, 041-046.	0.6	25
299	Safety of labor epidural anesthesia for women with severe hypertensive disease. American Journal of Obstetrics and Gynecology, 1999, 181, 1096-1101.	0.7	58
300	The Preterm Prediction Study: Effect of gestational age and cause of preterm birth on subsequent obstetric outcome. American Journal of Obstetrics and Gynecology, 1999, 181, 1216-1221.	0.7	401
301	The Preterm Prediction Study: Failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 1999, 180, 1151-1154.	0.7	33
302	Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. American Journal of Obstetrics and Gynecology, 1998, 179, 1193-1199.	0.7	31
303	Predictors of pre-eclampsia in women at high risk. American Journal of Obstetrics and Gynecology, 1998, 179, 946-951.	0.7	125
304	The preterm prediction study: Risk factors for indicated preterm births. American Journal of Obstetrics and Gynecology, 1998, 178, 562-567.	0.7	293
305	The Preterm Prediction Study: Recurrence risk of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 1998, 178, 1035-1040.	0.7	231
306	The effect of oral terbutaline on maternal glucose metabolism and energy expenditure in pregnancy. American Journal of Obstetrics and Gynecology, 1998, 178, 1041-1047.	0.7	19

#	Article	IF	CITATIONS
307	Risk Factors for Preeclampsia, Abruptio Placentae, and Adverse Neonatal Outcomes among Women with Chronic Hypertension. New England Journal of Medicine, 1998, 339, 667-671.	13.9	472
308	Low-Dose Aspirin to Prevent Preeclampsia in Women at High Risk. New England Journal of Medicine, 1998, 338, 701-705.	13.9	633
309	The Preterm Prediction Study: Association of cesarean delivery with increases in maternal weight and body mass index. American Journal of Obstetrics and Gynecology, 1997, 177, 333-341.	0.7	84
310	The preterm prediction study: Patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. American Journal of Obstetrics and Gynecology, 1997, 177, 8-12.	0.7	85
311	The preterm prediction study: Fetal fibronectin, bacterial vaginosis, and peripartum infection. Obstetrics and Gynecology, 1996, 87, 656-660.	1.2	105
312	Contraction inhibition by \hat{l}^2 -agonists progressively decreases before labor in the rat myometrium. American Journal of Obstetrics and Gynecology, 1996, 174, 1637-1642.	0.7	5
313	The preterm prediction study: Risk factors in twin gestations. American Journal of Obstetrics and Gynecology, 1996, 175, 1047-1053.	0.7	324
314	Alterations in Ovine Myometrial \hat{l}^2 -Adrenergic Cascade Do Not Mediate Tachyphylaxis to Ritodrine. Journal of Maternal-Fetal and Neonatal Medicine, 1996, 5, 155-160.	0.7	0
315	Alterations in ovine myometrial ?-adrenergic cascade do not mediate tachyphylaxis to ritodrine. The Journal of Maternal-fetal Medicine, 1996, 5, 155-160.	0.2	3
316	Magnesium Sulfate Is a Poor Inhibitor of Oxytocin-Induced Contractility in Pregnant Sheep. Journal of Maternal-Fetal and Neonatal Medicine, 1995, 4, 139-143.	0.7	3
317	Prevention of Preeclampsia with Low-Dose Aspirin in Healthy, Nulliparous Pregnant Women. New England Journal of Medicine, 1993, 329, 1213-1218.	13.9	538
318	Effect of Nicardipine on Contraction Inhibition, \hat{l}^2 -Adrenergic Receptor Cascade, and Oxytocin Receptors. Journal of Maternal-Fetal and Neonatal Medicine, 1993, 2, 85-90.	0.7	1
319	A Pharmacokinetic Approach to Preterm Labor Inhibition. Journal of Maternal-Fetal and Neonatal Medicine, 1992, 1, 104-116.	0.7	7
320	Comparison of pulsatile and continuous ritodrine administration: Effects on uterine contractility and Î ² -adrenergic receptor cascade. American Journal of Obstetrics and Gynecology, 1991, 164, 1005-1011.	0.7	21
321	Pharmacokinetics and pharmacodynamics of ritodrine afterintramuscular administration to pregnant women. American Journal of Obstetrics and Gynecology, 1990, 162, 1215-1219.	0.7	14
322	Pharmacokinetics of ritodrine administered intravenously: Recommendations for changes in the current regimen. American Journal of Obstetrics and Gynecology, 1990, 162, 429-437.	0.7	38
323	Pharmacologic Treatment of Preterm Labor. Clinical Obstetrics and Gynecology, 1988, 31, 635-651.	0.6	41
324	A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor. American Journal of Obstetrics and Gynecology, 1984, 150, 7-14.	0.7	87

#	Article	IF	CITATIONS
325	Treatment of Preterm Labour A Review of the Therapeutic Options. Drugs, 1983, 26, 243-261.	4.9	37
326	Pharmacodynamics of ritodrine in pregnant women during preterm labor. American Journal of Obstetrics and Gynecology, 1983, 147, 752-759.	0.7	68
327	Pharmacologic inhibition of preterm labor. American Journal of Obstetrics and Gynecology, 1979, 133, 557-578.	0.7	80
328	Comparison of Cesarean Deliveries in a Multicenter U.S. Cohort Using the 10-Group Classification System. American Journal of Perinatology, 0, , .	0.6	0